105 related articles for article (PubMed ID: 15494771)
21. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
Ding L; Hua W; Niu H; Chen K; Zhang S
Europace; 2008 Sep; 10(9):1034-41. PubMed ID: 18559335
[TBL] [Abstract][Full Text] [Related]
24. The cost of implantable defibrillators: perceptions and reality.
Camm J; Klein H; Nisam S
Eur Heart J; 2007 Feb; 28(4):392-7. PubMed ID: 16887857
[TBL] [Abstract][Full Text] [Related]
25. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era.
Groeneveld PW; Matta MA; Suh JJ; Yang F; Shea JA
Pacing Clin Electrophysiol; 2007 Apr; 30(4):463-71. PubMed ID: 17437568
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
Adang E; Voordijk L; Jan van der Wilt G; Ament A
Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
[TBL] [Abstract][Full Text] [Related]
27. Benefits of the implantable cardioverter-defibrillator.
Epstein AE
J Am Coll Cardiol; 2008 Sep; 52(14):1122-7. PubMed ID: 18804737
[TBL] [Abstract][Full Text] [Related]
28. Expenditure and value for money: the challenge of implantable cardioverter defibrillators.
Boriani G; Biffi M; Martignani C; Diemberger I; Valzania C; Bertini M; Branzi A
QJM; 2009 May; 102(5):349-56. PubMed ID: 19276209
[TBL] [Abstract][Full Text] [Related]
29. [Prophylactic use of cardiac implantable defibrillators in patients with severe left ventricular dysfunction: how to deal with decision making among guidelines, clinical practice, ethical problems, and limited economic resources].
Berisso MZ; Caruso D; Canonero D; Setti S; Domenicucci S
G Ital Cardiol (Rome); 2008 May; 9(5):338-54. PubMed ID: 18678225
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator.
Hlatky MA; Sanders GD; Owens DK
Health Aff (Millwood); 2005; 24(1):42-51. PubMed ID: 15647214
[TBL] [Abstract][Full Text] [Related]
31. How should we cost ICD therapy?
Fox DJ; Davidson NC; Fitzpatrick AP
Int J Cardiol; 2007 May; 118(1):1-3. PubMed ID: 17258335
[No Abstract] [Full Text] [Related]
32. Downward delegation of implantable cardioverter defibrillator decision-making in a restricted-resource environment: the pitfalls of bedside rationing.
Simpson CS; Hoffmaster B; Dorian P
Can J Cardiol; 2005 May; 21(7):595-9. PubMed ID: 15940358
[TBL] [Abstract][Full Text] [Related]
33. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
34. [Primary prevention of sudden death - afraid of the truth].
Klein H
Dtsch Med Wochenschr; 2002 Oct; 127(41):2113. PubMed ID: 12397556
[No Abstract] [Full Text] [Related]
35. Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure.
Ozasa N; Morimoto T; Furukawa Y; Shizuta S; Nishiyama K; Kita T; Kimura T
Int J Cardiol; 2008 Jan; 123(2):213-6. PubMed ID: 17367883
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
37. Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation.
Goldberger Z; Elbel B; McPherson CA; Paltiel AD; Lampert R
J Am Coll Cardiol; 2005 Sep; 46(5):850-7. PubMed ID: 16139136
[TBL] [Abstract][Full Text] [Related]
38. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
[TBL] [Abstract][Full Text] [Related]
39. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations.
Gialama F; Prezerakos P; Maniadakis N
Appl Health Econ Health Policy; 2014 Feb; 12(1):41-9. PubMed ID: 24243517
[TBL] [Abstract][Full Text] [Related]
40. Implantable or external defibrillators for individuals at increased risk of cardiac arrest: where cost-effectiveness hits fiscal reality.
Cram P; Katz D; Vijan S; Kent DM; Langa KM; Fendrick AM
Value Health; 2006; 9(5):292-302. PubMed ID: 16961547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
